Page 3 - Aytu Bioscience News Today

– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available t...

Aytu BioScience, Inc.: Aytu BioScience to Present at Upcoming March Investor Conferences ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: Cowen 41 st Annual Healthcare Conference: A live virtual presentation wil...

A comprehensive new market research report on  GABA Receptor Agonist market published by DBMR gives details about historic data, present market trends, future product environment, marketing strategies, Strategic recommendations, Competitive Intelligence, emerging trends and the technical progress in the related industry. This intelligence report includes investigations based on Current scenarios, Historical records, and Future predictions. The report contains different market related to marke...

(2) Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / February 4, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal second quarter ended December 31, 2020 on February 11, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provid...

Health your username February 4, 2021 A Neos Therapeutics, Inc. shareholder has filed suit against the company and its board of directors for violations of the Securities Exchange Act of 1934, arising from the board’s attempt to sell the company to Aytu BioScience, Inc. through its wholly-owned subsidiary Neutron Acquisition Sub, Inc (together, Aytu). The Southern District of New York complaint, filed on Wednesday, contends that the defendants filed a materially incomplete and misleading regi...

Share this article Share this article NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated  Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating  Neos Therapeutics, Inc. ("NEOS" or the "Company") ( ) relating to its proposed merger with Aytu BioScience, Inc. Under the terms of the agreement, N...

Share: Osmotica Pharmaceuticals (NASDAQ: OSMT) shares were trading higher Monday in anticipation of a ruling by the FDA on the companys New Drug Application for Arbaclofen ER in patients with multiple sclerosis. Osmotica Pharmaceuticals is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and womens health products, which are primarily complex formulations of generic drugs. Osmotica Pharmaceuticals shares...

Share this article Share this article ResearchAndMarkets.coms offering. Global Gynecology Partnering 2010-2020: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the worlds pharmaceutical and biotechnology companies since 2010. Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensors product or technology. More often these days these deals tend to be multi-component incl...

(2) ENGLEWOOD, CO / ACCESSWIRE / December 15, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), ("Aytu" or "the Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today the closing of its previously announced underwritten public offering of 4,791,667 shares of common stock of the Company, which includes the full exercise of the underwriters option to purchase an additional 625,000 shares of common stock, at a price...

/PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Neos Therapeutics, Inc. (NASDAQ: NEOS) and its board of directors...